Literature DB >> 6201746

Cyclic nucleotides control a system which regulates Ca2+ sensitivity of platelet secretion.

D E Knight, M C Scrutton.   

Abstract

Cellular responses to extracellular signals are mediated by changes in the intracellular concentrations of one or more second messengers. In platelets, inhibitory agonists increase intracellular cyclic-3',5'-AMP [( cyclic AMP]i (refs 2, 3] whereas excitatory agonists increase [Ca2+]i and/or [1,2-diacylglycerol]i (refs 4-9), and in some cases decrease [cyclic AMP]i (refs 10, 11). Both activation and inhibition of platelet responses have been attributed to an increase in [cyclic-3',5'-GMP]i (refs 8, 12). The activity of protein kinase C, which is associated with the platelet secretory response, is increased by both 1,2-diacylglycerol and Ca2+ (refs 4, 7, 8). The role of cyclic AMP may involve either inhibition of Ca2+ mobilization to the cytosol or stimulation of intracellular Ca2+ uptake, and in addition inhibition of 1,2-diacylglycerol formation. The relationship between cyclic-3',5'-GMP (cyclic GMP) and other second messengers in platelet activation has not been defined. Using platelets made permeable by exposure to an intense electric field, we demonstrate here modulation of the Ca2+ sensitivity of platelet secretion by thrombin, and by 12-O-tetradecanoylphorbol-13-acetate (TPA) and 1-oleyl-2- acetylglycerol ( OAG ), both potent activators of protein kinase C. The effect of thrombin is selectively modified by cyclic GMP and cyclic AMP. The response to OAG and TPA is also modulated by cyclic AMP but to a much lesser extent.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6201746     DOI: 10.1038/309066a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  26 in total

1.  A diacylglycerol kinase inhibitor, R59022, potentiates secretion by and aggregation of thrombin-stimulated human platelets.

Authors:  D L Nunn; S P Watson
Journal:  Biochem J       Date:  1987-05-01       Impact factor: 3.857

2.  Prostaglandin E1 and forskolin antagonize C-kinase activation in the human platelet.

Authors:  D de Chaffoy de Courcelles; P Roevens; H Van Belle
Journal:  Biochem J       Date:  1987-05-15       Impact factor: 3.857

3.  Liberation of [3H]arachidonic acid and changes in cytosolic free calcium in fura-2-loaded human platelets stimulated by ionomycin and collagen.

Authors:  W K Pollock; T J Rink; R F Irvine
Journal:  Biochem J       Date:  1986-05-01       Impact factor: 3.857

Review 4.  Co-existence between receptors, carriers, and second messengers on astrocytes grown in primary cultures.

Authors:  E Hansson
Journal:  Neurochem Res       Date:  1989-09       Impact factor: 3.996

5.  Cyclic nucleotide phosphodiesterase inhibition by a benzoic acid derivative.

Authors:  J J Killackey; B A Killackey; R B Philp
Journal:  Agents Actions       Date:  1985-12

6.  Release of Ca2+ by inositol 1,4,5-trisphosphate in platelet membrane vesicles is not dependent on cyclic AMP-dependent protein kinase.

Authors:  F O'Rourke; G B Zavoico; M B Feinstein
Journal:  Biochem J       Date:  1989-02-01       Impact factor: 3.857

Review 7.  Gaining access to the cytosol: the technique and some applications of electropermeabilization.

Authors:  D E Knight; M C Scrutton
Journal:  Biochem J       Date:  1986-03-15       Impact factor: 3.857

8.  Action of guanosine 5'-[beta-thio]diphosphate on thrombin-induced activation and Ca2+ mobilization in saponin-permeabilized and intact human platelets.

Authors:  K S Authi; G H Rao; B J Evenden; N Crawford
Journal:  Biochem J       Date:  1988-11-01       Impact factor: 3.857

9.  Effects of prostaglandin I2 and forskolin on the secretion from platelets evoked at basal concentrations of cytoplasmic free calcium by thrombin, collagen, phorbol ester and exogenous diacylglycerol.

Authors:  T J Rink; A Sanchez
Journal:  Biochem J       Date:  1984-09-15       Impact factor: 3.857

Review 10.  Current issues in thrombosis prevention with antiplatelet drugs.

Authors:  G de Gaetano; C Cerletti; E Dejana; J Vermylen
Journal:  Drugs       Date:  1986-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.